Stockreport

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

Veru Inc.  (VERU) 
Last veru inc. earnings: 2/12 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: verupharma.com/investors
PDF --Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high [Read more]